A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset.

Trial Profile

A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs JTV 519 (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TUNDRA-AF
  • Sponsors Sequel Pharmaceuticals
  • Most Recent Events

    • 13 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Actual initiation date (February 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top